Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes

European Journal of Endocrinology

Volumn 158, Issue 1, 2008, Pages 35-46

  Lund, Søren S ^a   Tarnow, Lise ^a   Frandsen, Merete ^a   Smidt, Ulla M ^a   Pedersen, Oluf ^a,b   Parving, Hans Henrik ^b,c   Vaag, Allan A ^a,d  

^a STENO DIABETES CENTER   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; FAT; FATTY ACID; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PROTEIN; REPAGLINIDE; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET THERAPY; DOUBLE BLIND PROCEDURE; FATTY ACID BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TEST MEAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; AREA UNDER CURVE; BLOOD GLUCOSE; CARBAMATES; CHOLESTEROL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; METFORMIN; MIDDLE AGED; PIPERIDINES; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 38949105920     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0500     Document Type: Article

References (65)

1. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K & Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic: subjects with and without prior myocardial infarction. New England Journal of Medicine 1998 339 229-234.
2. Stamler J. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993 16 434-444.
3. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe. Lancet 1999 354 617-621.
4. Stampfer MJ. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. Journal of the American Medical Association 1996 276 882-888.
5. Nordestgaard BG, Benn M, Schnohr P & Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. Journal of the American Medical Association 2007 298 299-308.
6. Ferrannini E, Simonson DC, Katz LD, Reichard G, Bevilacqua S, Barrett El, Olsson M & DeFronzo RA. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism: Clinical and Experimental 1988 37 79-85.
7. Rivellese AA, De-Natale C, Di-Marino L, Patti L, Iovine C, Coppola S, Del-Prato S, Riccardi G & Annuzzi G. Exogenous and endogenous postprandial lipid abnormalities in type 2 diabetic patients with optimal blood glucose control and optimal fasting triglyceride levels. Journal of Clinical Endocrinology and Metabolism 2004 89 2153-2159.
8. Iovine C, Vaccaro O, Gentile A, Romano G, Pisanti F, Riccardi G & Rivellese AA. Post-prandial triglyceride profile in a population-based sample of type 2 diabetic patients. Diabetologia 2004 47 19-22.
9. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003 46 733-749.
10. Cohn JS, McNamara JR & Schaefer EJ. Lipoprotein cholesterol concentrations in the plasma of human subjects as measured in the fed and fasted states. Clinical Chemistry 1988 34 2456-2459.
11. Lund S, Petersen M, Frandsen M, Carstensen B, Parving HH, Dyerberg J & Jensen T. Sustained postprandial decrease in LDL-cholesterol (LDL-C) in patients with type-2 diabetes mellitus (T2DM). Diabetes 2003 52 A213.
12. Lechleitner M. Low-density lipoproteins of the postprandial state induce cellular cholesteryl ester accumulation in macrophages. Arteriosclerosis and Thrombosis 1994 14 1799-1807.
13. Cianflone K, Dahan S, Monge JC & Sniderman AD. Pathogenesis of carbohydrate-induced hypertriglyceridemia using HepG2 cells as a model system. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology/American Heart Association 1992 12 271-277.
14. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G & Fogari R. Comparison of glycaernic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Research and Clinical Practice 2003 60 161-169.
15. Furlong NJ, Hulme SA, O'Brien SV & Hardy KJ. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes Care 2002 25 1685-1690.
16. Ceriello A, Eckland DJ, Johns D, Gilmore KJ, Widel M & Tan MH. Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 2005 28 266-272.
17. Heine RJ & Dekker JM. Beyond postprandial hyperglycaemia: metabolic factors associated with cardiovascular disease. Diabetologia 2002 45 461-475.
18. Esposito K, Giugliano D, Nappo F & Marfella R. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004 110 214-219.
19. Majali KA, Cooper MB, Staels B, Luc G, Taskinen M-R & Betteridge DJ. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 2006 49 527-537.
20. Phillips C. Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis 2000 148 283-291.
21. Reaven GM. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control. Journal of Clinical Endocrinology and Metabolism 1992 74 1020-1026.
22. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET & Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism: Clinical and Experimental 2004 53 159-164.
23. Miles JM, Wooldridge D, Grellner WJ, Windsor S, Isley WL, Klein S & Harris WS. Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy. Diabetes 2003 52 675-681.
24. Singhal P, Caumo A, Cobelli C & Taylor R. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. Metabolism 2005 54 79-84.
25. Rizzo MR, Barbieri M, Grella R, Passariello N & Paolisso G. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes and Metabolism 2005 31 255-260.
26. Vakkilainen J, Mero N, Schweizer A, Foley JE & Taskinen MR. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes. Diabetes/Metabolism Research and Reviews 2002 18 484-490.
27. Skarfors ET, Selinus KI & Lithell HO. Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. BMJ 1991 303 755-760.
28. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski A, Rosner B, Arky RA, Speizer FE & Flennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Archives of Internal Medicine 1991 151 1141-1148.
29. Arner P, Pollare T & Lithell H. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 1991 34 483-487.
30. Hundal RS & Inzucchi SE. Metformin: new understandings, new uses. Drugs 2003 63 1879-1894.
31. Culy CR & Jarvis B. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 2001 61 1625-1660.
32. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, Smidt UM, Pedersen O, Parving HH & Vaag A. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes, Obesity and Metabolism 2007 9 394-407.
33. Leatherdale BA. Acute antihyperglycaemic effect of metformin without alteration of gastric emptying. IRCS Medical Science 1986 14 1085-1086.
34. Grosskopf I, Ringel Y, Charach G, Maharshak N, Mor R, Iaina A & Weintraub M. Metformin enhances clearance of chylomicrons and chylomicron remnants in nondiabetic mildly overweight glucose-intolerant subjects. Diabetes Care 1997 20 1598-1602.
35. Wu MS, Johnston P, Shen VVH, Hollenbeck CB, Jeng CY, Goldfine ID, Chen YD & Reaven GM. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care 1990 13 1-8.
36. Jeppesen J. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care 1994 17 1093-1099.
37. Hollenbeck CB. Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabetes and Metabolism 1991 17 483-489.
38. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
39. Friedewald WT, Levy RI & Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifugation. Clinical Chemistry 1972 18 499-502.
40. Altman DG. Serial measurements. In Practical Statistics for Medical Research, pp 426-433. Ed. DG Altman, London: Chapman & Hall/CRC London, UK/Boca Raton, USA, 1999.
41. Brown H & Prescott R. Applied Mixed Models in Medicine. 2 West Sussex, UK: John Wiley & Sons, Ltd, 2006.
42. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S & Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. New England Journal of Medicine 1996 334 952-957.
43. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F. Poli M, Perbellini S, Raffaelli A, Cacciatori V, Santi L, Targher G, Bonadonna R & Muggeo M. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002 25 1135-1141.
44. Wallace TM, Levy JC & Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004 27 1487-1495.
45. National Institutes of Health, National Heart Lung and Blood Institute, National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. NIH Publication No. 02-5215. 2002.
46. van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ & Khaw KT. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Annals of Internal Medicine 2007 146 640-648.
47. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR & Holman RR. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998 316 823-828.
48. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr & Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 110 227-239.
49. Johnson CL, Rifkind BM, Sempos CT, Carroll MD, Bachorik PS, Briefel RR, Gordon DJ, Burt VL, Brown CD & Lippel K. Declining serum total cholesterol levels among US adults. The National Health and Nutrition Examination Surveys. Journal of the American Medical Association 1993 269 3002-3008.
50. Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. Journal of the American College of Cardiology 1994 23 1273-1277.
51. Knopp RH. Drug treatment of lipid disorders. New England Journal of Medicine 1999 341 498-511.
52. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 2006 29 (Suppl. 1) S4-S42.
53. Jacobs MJ, Kleisli T, Pio JR, Malik S, L'Italien GJ, Chen RS & Wong ND. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Research and Clinical Practice 2005 70 263-269.
54. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD & Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. Journal of Internal Medicine 2004 256 1-14.
55. Buse JB, Tan MH, Prince MJ & Erickson PP. The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2004 6 133-156.
56. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB & Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine 2007 147 386-399.
57. Tentolouris N, Kolia M, Tselepis AD, Perea D, Kitsou E, Kyriaki D, Tambaki AP, Karabina SP, Sala C, Fragoulopoulos E & Katsilambros N. Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus. Experimental and Clinical Endocrinology and Diabetes 2003 111 370-373.
58. Collins R, Armitage J, Parish S, Sleigh P, Peto R & Heart PSCG. MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 2005-2016.
59. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A & Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. Journal of the American Medical Association 2003 290 486-494.
60. Dubois C, Armand M, Mekki N, Portugal H, Pauli AM, Bernard PM, Lafont H & Lairon D. Effects of increasing amounts of dietary cholesterol on postprandial lipemia and lipoproteins in human subjects. Journal of Lipid Research 1994 35 1993-2007.
61. Blackburn P, Cote M, Lamarche B, Couillard C, Pascot A, Tremblay A, Bergeron J, Lemieux I & Despres JP. Impact of postprandial variation in triglyceridemia on low-density lipoprotein particle size. Metabolism: Clinical and Experimental 2003 52 1379-1386.
62. Karpe F, Tornvall P, Olivecrona T, Steiner G, Carlson LA & Hamsten A. Composition of human low density lipoprotein: effects of postprandial triglyceride-rich lipoproteins, lipoprotein lipase, hepatic lipase and cholesteryl ester transfer protein. Atherosclerosis 1993 98 33-49.
63. Dubois C, Beaumier G, Juhel C, Armand M, Portugal H, Pauli AM, Borel P, Latge C & Lairon D. Effects of graded amounts (0-50 g) of dietary fat on postprandial lipemia and lipoproteins in normolipidemic adults. American Journal of Clinical Nutrition 1998 67 31-38.
64. Cohen JC, Noakes TD & Benade AJ. Serum triglyceride responses to fatty meals: effects of meal fat content. American Journal of Clinical Nutrition 1988 47 825-827.
65. Lewis GF. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. Journal of Clinical Endocrinology and Metabolism 1991 72 934-944.